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Purpose: The incidence of colorectal cancer (CRC) in Korea has increased remarkably during the past few decades. The 
present study investigated the characteristics and survival of patients with CRC in Korea as a function of time, tumor dis-
tribution, stage, sex, and age.
Methods: We retrieved clinical data on 326,712 CRC patients diagnosed between 1996 and 2015 from the Korea Central 
Cancer Registry. The incidence and the 5-year relative survival rates were compared across time period, tumor distribu-
tion, stage, sex, and age group.
Results: The percentage of patients with colon cancer increased from 49.5% in 1996–2000 to 66.4% in 2011–2015 while 
the percentage of patients with rectal cancer decreased from 50.5% to 33.6%. The 5-year relative survival rates for all 
CRCs improved from 58.7% in 1996–2000 to 75.0% in 2011–2015. For 1996–2000, survival rates were highest for patients 
with left-sided colon cancers, followed by those with right-sided, transverse, rectal, rectosigmoid cancers. For 2011–2015, 
the survival rates for patients with left-sided cancers were highest, followed by those with rectosigmoid, rectal, transverse, 
and right-sided colon cancers. Patients with local and regional, but not distant, SEER (Surveillance, Epidemiology, and 
End Results) stage tumors experienced significantly increased survival rates for 2006–2010 and 2011–2015. The propor-
tion of CRC patients by age decreased in the order ≥70, 60–69, 50–59, 40–49, ≤39 years whereas survival rates decreased 
in the order 50–59, 60–69, 40–49, ≤39, ≥70 years. 
Conclusion: Korean CRC has some distinct characteristics and survival patterns in terms of tumor distribution, stage, sex, 
and age. With time, survival outcomes have improved for both local and regional, but not distant, stage tumors.
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INTRODUCTION
According to 2015 Korean cancer statistics [1], colorectal cancer 
(CRC) is the 2nd most common type of cancer, followed by stom-
ach cancer, with 26,790 cases nationwide in 2015. The annual 
standardized incidence rate of CRC increased by 6.0% annually 
between 1999 and 2010 and then decreased from 2010 to 2015 by 
6.1%. The age-standardized incidence rate in 2015 was 30.4/ 
100,000, making this the third most common cancer during this 
period. The age-standardized mortality rate for CRCs increased 
until 2004 by 5.5% annually and then began to decrease between 
2004 and 2015 by 1.3% annually. The age-standardized rate of 
death from CRC per 100,000 in 2016 was 16.5, with CRC serving 
as the 3rd leading cause of death across all cancers in that year. 
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Not only have the incidence and the mortality rates associated 
with these cancers changed over time, but so have the diagnosis 
and the treatment strategies for patients with CRCs, leading to 
significant improvements in the oncologic outcomes in Korea [2-
4]. 
While others (e.g., Park et al. [5]) have previously reported the 
characteristics and the survival rates for patients with CRCs from 
1993 to 2010, current rates should also be assessed as they have 
changed [1]. In addition, previous work did not investigate 
changes in frequency or survival rates per SEER (Surveillance, 
Epidemiology, and End Results) summary stage as the Korea 
Central Cancer Registry (KCCR) only began to report SEER 
summary stage data in 2006.
Since 1999, nationwide cancer incidence data have been re-
corded in the KCCR, which serves to collect information on can-
cer patients from registered hospitals. Additionally, the KCCR 
and regional cancer registries have directly surveyed information 
on previously unreported cancer patients by using a national in-
surance database. The KCCR is thought to include data from all 
cancer patients in Korea, making it an ideal tool for the analyses 
conducted here [1]. The purpose of this study was to investigate 
the characteristics of Korean patients with CRC, focusing on sur-
vival outcomes across tumor distribution, stage, and patient sex 
and age by using data from a nationwide cancer registry. Changes 
in survival rates were also assessed across discrete time periods or 
epochs.
METHODS
We retrieved clinical data on 326,712 patients with CRC diag-
nosed between 1996 and 2015. Pathologically-identified adeno-
carcinomas of the colon and rectum were included in the present 
study. Patient age, sex, and clinical data (such as tumor distribu-
tion and stage) were retrieved from the Korea National Cancer In-
cidence Database and used for analyses. This study was exempted 
from approval and informed consent by the Institutional Review 
Board of Severance Hospital Yonsei University Health System.
Relative survival rates (RSRs) were calculated across predefined 
5-year time periods: 1996–2000, 2001–2005, 2006–2010, 2006–
2010, and 2011–2015. Trends in relative survival from CRC by di-
agnostic year were illustrated using the Kaplan-Meier method. 
Tumor location was classified according to the following catego-
ries: the right side of the colon (from the cecum, including the ap-
pendix, to the colon’s hepatic flexure), transverse colon, left side of 
the colon (from the splenic flexure to the sigmoid colon), recto-
sigmoid, and the rectum. SEER stages (local, regional, and dis-
tant) were available for patients identified from 2006 to 2015. In 
brief, SEER local stage data included tumors confined to their ori-
gin organ (i.e., colon or rectum) without lymph-node metastasis. 
Regional disease included tumors with adjacent organ invasion or 
regional lymph-node metastasis. Distant disease included those 
with distant site metastasis. A comparison of SEER stages across 
TNM stages is shown in supplementary Table 1. The 5-year RSR 
was adjusted for the mortality expected among others of the same 
Fig. 1. Trends in the tumor distribution according to time period 
from 1996 to 2015 in Korea. (A) Both sexes, (B) male, and (C) fe-
male.
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age and sex. The RSRs were calculated using the Ederer II method 
[6]. Log-rank tests were used to test for differences in survival 
rates.
Estimated survival rates were compared across tumor distribu-
tion, stage, patient’s sex (male and female), and patient’s age at di-
agnosis (≤39, 40–49, 50–59, 60–69, and ≥70 years). All statistical 
analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, 
NC, USA), and statistically significance was considered to be in-
dicated by a P-value of less than 0.05.
RESULTS
Distribution of CRC according to tumor site, stage, and 
patient’s sex and age
Korean CRC tumor distribution statistics have changed annually. 
The rate of colon cancer increased from 49.5% in 1996–2000 to 
66.4% in 2011–2015. Right-sided colon cancers increased from 
15.9% to 20.0%, transverse colon cancers from 4.1% to 4.9%, left-
sided colon cancers from 22.9% to 31.9%, and rectosigmoid junc-
tion cancers from 6.6% to 9.6%. However, the total rate of rectal 
cancer decreased from 50.5% to 33.6% during the same period. 
This change was observed in both males and females. The pro-
portion of right-sided colon cancers in females increased steeply 
and was higher than that among males (25.4% vs. 16.4%) between 
2011 and 2015. The proportion of left-sided colon cancers in fe-
males had a similar trend from 1996 to 2015. The proportion of 
left-sided colon and rectal cancers in males was higher than in fe-
males between 2001 and 2015 (Fig. 1). 
In both time periods (2006–2010 and 2011–2015), a regional 
tumor stage designation was more common than a local stage 
designation. From 2011 to 2015, the proportion of all tumors with 
a regional stage designation across both sexes was 43.4%; 35.3% 
were local stage tumors, and 15.9% were distant stage tumors. 
This order was evident among both male and female patients 
when analyzed independently (Fig. 2). 
The incidence of CRC by age in both time periods decreased in 
the following order: ≥70, 60–69, 50–59, 40–49, and ≤39 years (Fig. 
3). In patients aged 50–59 and 60–69, the proportion of local stage 
tumors was higher than in the other age groups. Those aged 40–
49 and ≥70 years had similar proportions of tumors distributed 
across SEER stages. Those aged less than 39 had the highest pro-
portion of advanced stage tumors (regional, 47.1% and distant, 
20.8%) (Fig. 4). Those over 70 years of age had the highest pro-
portion of right-sided colon cancers of all age groups (24.2% vs. 
18.9% in those 60–69, 16.1% in those 50–59, 15.5% in those 40–
49, and 18.6% in those ≤39 years), though the proportion of rectal 
cancers was lower in these patients than in those of a younger age 
(31.6% vs. 32.6% in those 60–69, 36.2% in those 50–59, 38.4% in 
those 40–49, and 34.9% in those ≤39 years) (Fig. 5).
Fig. 2. Trends in the proportion of SEER (Surveillance, Epidemiology, and End Results) stage according to time period from 2006 to 2015 in 
Korea. 
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Fig. 3. Trends in the proportion of age according to time period from 
2006 to 2015 in Korea.
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RSRs for CRCs by tumor site, stage, and patient’s sex and 
age
The 5-year RSRs for patients with all CRCs and for those with 
right-sided colon, transverse colon, left-sided colon, rectosigmoid, 
and rectum cancers by time period are summarized in Table 1. 
Survival improved significantly across all tumor sites, with left-
sided colon cancers having the most favorable outcomes across all 
time periods (Fig. 6). In both the total cohort and among female 
patients, right-sided and transverse colon cancers had more fa-
vorable outcomes than did rectosigmoid and rectal cancers from 
1996 to 2000. In contrast, from 2001 to 2015, rectosigmoid and 
rectal cancers had more favorable survival outcomes than did 
right-sided or transverse colon cancers. In male patients, survival 
rates for right-sided and transverse colon cancers were higher 
than they were for rectosigmoid or rectal cancers across all time 
periods. Females had worse survival rates across the entire as-
sessed time period (Table 1). 
Survival rates according to SEER stage were compared between 
the 2006–2010 and the 2011–2015 time periods. Survival with lo-
cal or regional SEER stage tumors significantly increased from 
2006–2010 to 2011–2015 (92.8% vs. 94.7%, P < 0.0001 for local 
SEER stage; 78.8% vs. 81.6%, P < 0.0001 for regional SEER stage) 
and did not differ for distant stage tumors (19.7% vs. 19.6%, P = 
0.9859) (Table 2). Survival rates for patients with local stage tu-
mors increased between the 2006–2010 and the 2011–2015 time 
periods by more than 90% while survival rates for those with re-
gional stage CRC tumors increased annually, with survival rates 
for patients with regional stage colon cancer tumors increasing by 
more than 80% from 2011 to 2015. However, survival rates for 
patients with rectal cancers were 76.1% for the 2006–2010 time 
period and 78.9% for the 2011–2015 period. Survival rates for pa-
tients with distant stage colon cancer tumors on the left side of the 
colon increased from 21.8% in 2006–2010 to 23.3% in 2011–2015. 
Right-sided colon, transverse colon, rectosigmoid, and rectal can-
cer tumors with a distant stage classification were associated with 
decreased survival rates from 2006–2010 to 2011–2015. This was 
especially true for right-sided and transverse colon cancers of a 
distant stage, which had lower survival than left-sided colon, rec-
Fig. 4. Trends in the proportion of SEER (Surveillance, Epidemiology, and End Results) stage according to age from 2011 to 2015 in Korea. 
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Fig. 5. Trends in the tumor distribution according to age from 2011 to 2015 in Korea.
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tosigmoid, and rectal cancers (Table 3).
More favorable overall survival rates were found in certain age 
groups, with the survival rate decreasing in the following order in 
both the 2006–2010 and the 2011–2015 time periods: 50–59, 60–
69, 40–49, ≤39, and ≥70 years. This order was the same for those 
with local stage tumors. Those aged 50–59 and 60–69 had the 
most favorable overall survival outcomes, with rates over 80% in 
the 2011–2015 time period (82.1% and 81.2%, respectively). 
Those above 70 years of age had the worst overall survival rate at 
64.8% in 2011–2015. For patients with regional stage tumors, 
those aged 40–49 had more favorable survival outcomes than 
those aged 60–69. For patients with distant stage tumors, the most 
favorable survival outcome was found among those aged 40–49 
(Table 4).
In patients with transverse colon, left-sided colon, rectosigmoid, 
and rectal cancers, those aged 50–59 had more favorable survival 
rates, with the order of survival by age group  proceeding in the 
same order as it did for the overall cohort (listed above). Those 
younger than 39 had the best survival rates for right-sided colon 
cancers while those older than 40 had the highest survival rates 
for left-sided colon cancers (Table 5).     
DISCUSSION
Due to advancements in the treatment of patients with CRC and 
the extraordinary efforts made by Korean clinicians, a steady im-
provement of CRC survival rates in Korea and globally, as evi-
denced in the present study and others, has occurred across the 
Fig. 6. Trends in relative survival of patients with colorectal cancer according to tumor distribution by year after diagnosis from 1996 to 2015 
in Korea. (A) Right side colon (C18.0–18.3), (B) transverse colon (C18.4), (C) left side colon (C18.5–18.7), (D) rectosigmoid (C19.9), and (E) 
rectum (C20.9).
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Table 1. Trends in 5-year relative survival by tumor distribution according to time period
Sex and tumor sites 1996–2000 2001–2005 2006–2010 2011–2015 Absolute change (%)a
Both sexes
   Colon & rectum (C18–C20) 38,739 (58.7) 66,935 (66.2) 101,579 (72.6) 119,459 (75.0) 16.3
   Right side colon (C18.0–18.3) 5,577 (63.1) 10,519 (65.6) 17,323 (71.0) 22,664 (73.0) 9.9
   Transverse colon (C18.4) 1,430 (62.1) 2,518 (65.4) 4,261 (71.4) 5,505 (74.6) 12.5
   Left side colon (C18.5–18.7)  8,013 (64.0) 16,099 (70.0) 29,487 (75.9) 36,155 (78.3) 14.3
   Rectosigmoid (C19.9) 2,318 (56.9) 4,067 (67.1) 7,142 (74.4) 10,906 (75.1) 18.2
   Rectum (C20.9) 17,653 (57.7) 28,290 (66.7) 36,748 (72.3) 38,030 (74.6) 16.9
Men
   Colon & rectum (C18–C20) 21,269 (59.7) 38,266 (68.0) 60,504 (74.5) 71,522 (76.8) 17.1
   Right side colon (C18.0–18.3) 2,797 (66.0) 5,229 (69.2) 8,838 (74.9) 11,079 (76.2) 10.2
   Transverse colon (C18.4) 758 (66.1) 1,381 (68.4) 2,444 (74.7) 3,141 (78.8) 12.7
   Left side colon (C18.5–18.7)  4,566 (66.4) 9,567 (72.1) 18,151 (77.7) 22,550 (79.4) 13.0
   Rectosigmoid (C19.9) 1,322 (57.2) 2,416 (68.5) 4,404 (75.3) 6,825 (75.8) 18.6
   Rectum (C20.9) 9,878 (56.9) 16,628 (66.7) 22,649 (72.7) 24,158 (75.4) 18.5
Women   
   Colon & rectum (C18–C20) 17,470 (57.6) 28,669 (63.8) 41,075 (69.8) 47,937 (72.3) 14.7
   Right side colon (C18.0–18.3)   2,780 (60.1) 5,290 (62.0) 8,485 (67.0) 11,585 (69.9) 9.8
   Transverse colon (C18.4) 672 (57.7) 1,137 (61.8) 1,817 (67.0) 2,364 (68.9) 11.2
   Left side colon (C18.5–18.7) 3,447 (60.9) 6,532 (66.9) 11,336 (73.2) 13,605 (76.5) 15.6
   Rectosigmoid (C19.9) 996 (56.4) 1,651 (65.2) 2,738 (73.0) 4,081 (73.9) 17.5
   Rectum (C20.9) 7,775 (58.6) 11,662 (66.7) 14,099 (71.5) 13,872 (73.1) 14.5
Values are presented number (%).
aPercentage change in 5-year relative survival from 1996 to 2000 and 2011 to 2015.
Table 2. Five-year relative survival by SEER stage between 2006–2010 and 2011–2015
SEER stage
Both sexes
Changea
Male
Changea
Female
Changea
2006–2010 2011–2015 2006–2010 2011–2015 2006–2010 2011–2015
Overall 101,579 (72.6) 119,459 (75.0) 2.4 60,504 (74.5) 71,522 (76.8) 2.3 41,075 (69.8) 47,937 (72.3) 2.5
Local 33,734 (92.8) 42,142 (94.7) 1.9 20,904 (94.1) 26,319 (95.9) 1.8 12,830 (90.6) 15,823 (92.7) 2.1
Regional 41,618 (78.8) 51,901 (81.6) 2.8 24,479 (80.0) 30,602 (82.4) 2.4 17,139 (77.2) 21,299 (80.5) 3.3
Distant 15,557 (19.7) 18,943 (19.6) -0.1 8,954 (20.0) 10,976 (20.5) 0.5 6,603 (19.3) 7,967 (18.3) -1
Unknown 10,670 (61.3) 6,473 (54.0) -7.3 6,167 (65.0) 3,625 (58.8) -6.2 4,503 (56.3) 2,848 (47.9) -8.4
Values are presented number (%).
SEER, Surveillance, Epidemiology, and End Results.
aPercentage change in 5-year relative survival from 1996 to 2000 and 2011 to 2015.
Table 3. Five-year relative survival of all patients by tumor distribution and SEER stage between 2006–2010 and 2011–2015
SEER 
  stage
Right side colon 
(C18.0–C18.3)
Transverse colon 
(C18.4)
Left side colon 
(C18.5–18.7)
Rectosigmoid 
(C19.9)
Rectum 
(C20.9)
2006–2010 2011–2015 2006–2010 2011–2015 2006–2010 2011–2015 2006–2010 2011–2015 2006–2010 2011–2015
Overall 17,323 (71.0) 22,664 (730) 4,261 (71.4) 5,505 (74.6) 29,487 (75.9) 36,155 (78.3) 7,142 (74.4) 10,906 (75.1) 36,748 (72.3) 38,030 (74.6)
Local 4,975 (93.8) 7,027 (95.0) 1,308 (93.8) 1,854 (95.4) 10,025 (95.0) 13,255 (96.5) 2,074 (93.5) 3,169 (96.0) 12,882 (91.0) 13,962 (93.4)
Regional 8,036 (77.8) 10,837 (80.5) 1,914 (78.0) 2,604 (80.8) 12,141 (83.5) 15,427 (85.7) 3,323 (81.6) 5,523 (83.5) 14,963 (76.1) 16,381 (78.9)
Distant 2,924 (18.0) 3,951 (17.8) 675 (16.7) 819 (15.1) 4,831 (21.8) 5,942 (23.3) 1,073 (21.3) 1,835 (19.5) 4,907 (20.6) 5,356 (19.6)
Unknown 1,388 (62.0) 849 (49.7) 364 (57.2) 228 (49.5) 2,490 (67.5) 1,531 (58.6) 672 (64.2) 379 (45.3) 3,996 (60.4) 2,331 (55.6)
Values are presented number (%).
SEER, Surveillance, Epidemiology, and End Results.
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last several decades. A recent study of global cancer survival rates, 
including individual data from 25,676,887 patients across 279 
population-based registries in 67 countries from 1995 to 2009, in-
cluded data on colon cancer, specifically, for 3,613,067 patients [7]. 
For patients diagnosed with colon cancer between 2005 and 2009, 
the age-standardized 5-year net survival rates were 50%–59% in 
many countries. Specifically in Korea, the 5-year survival rate was 
42.5% between 1995 and 1999, though this increased to 60.4% 
between 2000 and 2004 and further to 66.0% between 2005 and 
2009. These survival outcomes were better than those in the other 
countries assessed, including a survival rate of 64.7% in the 
United States and 64.4% in Japan. Rectal cancer data from this 
large study are also available for 1,413,861 patients. For patients 
diagnosed with rectal cancer between 2005 and 2009, the age-
standardized 5-year net survival rates were 50%–59% in many 
countries. Survival rates were especially high in Korea, at 51.6% 
between 1995 and 1999, 60.8% between 2000 and 2004, and 
65.9% between 2005 and 2009. As with colon cancer, these rectal 
cancer survival rates are better than the other assessed rates, in-
cluding the rate in the United States (64.0%) or Japan (60.3%).
An anatomical rightward-shift in CRC incidence rates has also 
been reported in recent studies [8-12]. For example, the Ameri-
can Cancer Society reported a higher proportion of right-sided 
colon cancers (41%) than left-sided ones (22%) in the United 
States from 2009 to 2013. However, a striking variation in this dis-
tribution is seen by patient’s sex and age at diagnosis. In the 
United States, the likelihood of a proximal tumor location is 
greater in women than in men and increases with age. For exam-
ple, 57% of CRCs in women aged 80 years and older occur in the 
proximal colon versus just 26% in men younger than 50 years of 
age. Among both men and women younger than 50, of all the re-
gions assessed, CRC tumors are most commonly diagnosed in the 
rectum (41% and 36%, respectively) [12]. In the present study, fe-
males and those older than 70 years of age had a higher propor-
tion of right-sided colon cancers than did males and those in 
younger age groups. Otherwise, men and those aged below 60 
had the highest proportion of rectal cancers. 
Data revealed in the present study compare well to those re-
ported previously. A steep increase in right-sided colon cancers in 
females was observed in this study. Similarly, in Europe, the pro-
portion of CRCs presenting in the proximal colon has increased 
significantly from 27% to 32% in men and from 35% to 41% in 
women between the period from 1994 to 1997 and that from 2010 
to 2012 [13]. The increase in distal colon cancers, followed by 
proximal colon cancers, reported by previous studies [9-11] was 
also observed in the present study. Additionally, a steady decrease 
in the incidence of rectal cancers reported in the present study has 
also been reported by others. Overall, the Japanese and the Israeli 
populations have been found to have the highest incidence rates 
for cancers in the proximal and distal colon while those in Israel 
and China have the lowest incidence rates of rectal cancers [3, 14].
An increase in the survival rates across time in all tumor catego-
ries studied here was observed in the present study. Typically, left-
sided colon cancers had more favorable associated outcomes than 
did right-sided colon cancers in all time periods assessed here. 
Notably, recent studies have also reported a worse prognosis asso-
ciated with right-side colon cancers [8-11], though no clear expla-
nation has been given for this trend. Other tumor differences may 
be less variable in terms of associated mortality. For instance, 
Weiss et al. [15] reported no difference between the 5-year mor-
tality rates associated with proximal and distal colon cancer tu-
mors. They found that while proximal colon tumors had a better 
prognosis in stage II, they had a worse prognosis in stage III. They 
suggested that this finding might be due to differences in tumor 
biology, including microsatellite instability (MSI). MSI-high can-
cers are more frequently found in stage II proximal colon cancers 
and are associated with a more favorable prognosis.
Primary tumors arising from the left and the right sides of the 
colon also differ in terms of their distinct chromosomal and mo-
lecular characteristics. High MSI, CIMP, and MLH1 methylation 
levels are more likely to occur in right-sided than left-sided colon 
cancers [16]. In contrast, higher chromosomal instability is ob-
served in left-sided colon cancers [17]. Frequently, genetic muta-
tions and distributions of CM5 subtypes differ between right- and 
left-sided CRCs (e.g., KRAS, BRAF, TGFbR2, and PI3KCA muta-
tions are more common in right-sided CRCs while TP53, APC, 
and KRAS mutations are more common in left-sided CRCs) [18]. 
Epidermal growth factor receptor (EGFR) and vascular endothe-
lial growth factor 1 expressions have also been reported to be sig-
nificantly higher in left-sided than in right-sided CRCs [19]. 
A difference in molecular pathways may underlie differences in 
the presentation and the clinical outcomes associated with CRCs 
of differing locations, though the reasons for these differences re-
main mostly unknown. Differential distributions of genomic 
CRC subtypes and other biologic features between left- and right-
sided CRCs may contribute to an inferior prognosis with ad-
vanced stage right-sided CRC and to an inferior prognosis with 
anti-EGFR therapy in right-sided CRC. In the present study, 
right-sided and transverse colon cancers were also associated with 
a poorer prognosis than were left-sided, rectosigmoid, and rectal 
cancers between 2001 and 2015. Tumors in the local and the re-
gional stages were further associated with lower survival rates 
when they were right-sided in transverse and rectosigmoid colon 
cancers, but not in rectal cancer, than when they were left-sided. 
Right-sided and transverse colon cancers were associated with 
poorer survival rates than were left-sided, rectosigmoid, and rec-
tal cancers of a distant stage.  
Above all, the most promising outcome from the present study 
is the improvement of survival rates for patients with rectal can-
cers over time. From 1996–2000, rectal cancers were associated 
with worse survival rates than were right-sided colon cancers 
(56.9% vs. 63.1%, respectively). After 2001, rectal cancer was as-
sociated with better survival rates than were right-sided colon 
cancers (74.6% vs. 73.0%, respectively, from 2011–2015). This in-
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creased survival may be due to improvements in and standardiza-
tions of surgical techniques, including the total mesorectal exci-
sion and the combined radical resection, for the treatment of lo-
cal, advanced rectal cancers [20, 21]. Furthermore, advances in 
pre- and postoperative adjuvant treatments, including chemo-
therapy and radiotherapy, have increased radical resection rates 
and decreased local recurrence rates in patients with CRC [22].      
The SEER staging system used here differs slightly from the 
TNM staging system. Localized colon cancer corresponding to 
stage I or IIA requires no adjuvant chemotherapy. Regional CRCs 
corresponding to stages IIB or IIC and stage III require adjuvant 
chemotherapy for colon cancer and chemoradiotherapy for rectal 
cancer. Local stage cancers have a 5-year survival rate that is ex-
tremely high (94.7% between 2011 and 2015, increased from 
92.8% between 2006 and 2010). Regional stage cancers have also 
experienced increased survival rates recently (from 78.8% be-
tween 2006 and 2010 to 81.6% between 2011 and 2015). Despite 
advances in chemotherapeutics over the past few decades, survival 
outcomes for distant stage CRCs have not improved between the 
2006–2010 and the 2011–2015 epochs (2-year survival rate: 40.2% 
vs. 40.7%, 5-year survival rate: 19.7% vs. 19.6%, respectively). Im-
proved surgical techniques and advanced instruments and sys-
tems may, however, further increase these survival rates and the 
qualities of life for patients with local and regional stage CRCs. 
Chemotherapy plays an important role as an adjuvant treatment 
for patients with regional stage CRCs and is a first-line treatment 
for patients with distant stage CRCs. However, target agents, such 
as bevacizumab and cetuximab, have demonstrated no significant 
improvements in survival outcomes for those with distant stage 
CRCs. Greater efforts must be made and multidisciplinary ap-
proaches that combine surgery, chemotherapy, and radiotherapy 
must be taken if the survival outcomes for patients with distant 
stage CRCs are to be improved. Furthermore, early CRC screen-
ing and increased rates of examination should be encouraged in 
public health domains to improve patient prognoses.
Public health issues surrounding cancer screening and diagno-
ses often interact with the patient’s sex and other characteristics. 
For example, males may be exposed to more colon cancer risk 
factors, including cigarette smoke and alcohol [23, 24]. Mean-
while, women are more likely to develop MSI-high proximal co-
lon cancers [25]. This may have led to improved prognoses in fe-
males, as has been reported previously [26]. However, the present 
study reports a contradictory result—worse survival rates in fe-
males. This difference was most prominent among those over 70, 
a finding which may be further attributed to poorer socioeco-
nomic associations among elderly women [27]. For example, el-
derly women tend to pursue and receive less aggressive therapy 
for advanced diseases. Additionally, these patients may be pre-
sented with fewer opportunities for regular health checks and dis-
ease screening.
CRC prognoses among younger patients remain a controversial 
issue. While some studies have reported that younger patients, in-
cluding those with later stage cancers and exhibiting more proxi-
mal, aggressive tumor histology [28], face a worse prognosis, oth-
ers have reported no worse prognosis among the young [29]. In 
the present study, middle aged (40–69 years) patients had the 
most favorable survival outcomes, followed by the youngest (≤39 
years) and the oldest (≥70 years) patients across all tumor stage 
categories. Those younger than 39 typically had the highest por-
tion of advanced stage cancers among all age groups, an associa-
tion that may have contributed to poorer survival outcomes in 
this group. The youngest patients had survival rates for right-
sided and transverse colon cancers comparable to those for mid-
dle-aged patients (40–69 years), though these rates differed for 
left-sided, rectosigmoid, and rectal cancers, for which younger 
patients had poorer survival rates. Patients over 70 years of age 
had poorer survival rates than younger patients, regardless of 
SEER stage and tumor location. 
The age-related associations revealed here may be attributed to 
several factors. In the present study, those older than 70 had the 
highest proportion of right-sided colon cancers and the lowest 
proportion of local stage tumors. Furthermore, elderly patients 
may receive less aggressive therapy, have a greater comorbidity 
burden, and have poorer performance scores. Treatment parity 
may underlie these differences. For instance, studies have demon-
strated that, given the same level of treatment, elderly patients 
have survival rates comparable to those of the younger compara-
tors [30]. Considering an ever-expanding elderly population, fu-
ture studies should examine this phenomenon in more detail to 
identify its causes and, thus, improve CRC treatment outcomes.
In summary, the findings presented here reveal that survival 
rates among patients with CRCs, and especially those with rectal 
cancer, have improved dramatically in recent years. Survival rates 
among patients with a local or regional SEER CRC tumor stage 
have also improved. Our study findings may lead to further mac-
roscopic insights into the nature of CRC and improved prognoses 
for patients with these cancers in South Korea.
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